VolitionRx Limited (NYSE American: VNRX) has highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter, underscoring the potential of the Nu.Q H3.1 test in improving patient care.
Multiple studies have demonstrated that the Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality. Most of the supporting research has been peer reviewed and published, with experts noting the consistency of findings across multiple countries and patient populations, according to the company.
Volition believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies. The company is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
For more details, the full press release can be accessed at https://ibn.fm/2IH3m.
Volition is a multinational company focused on advancing the science of epigenetics. Its research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. Further information about the company is available at https://volition.com/.
